ENO1 and colorectal carcinoma: Therefore, targeting ENO1 might improve the sensitivity to chemotherapy and reduce the resistance to oxaliplatin and 5-fluorouracil (5-FU) by inhibiting F. nucleatum-induced glycolysis in CRC patients [49].